VivoSeq
Neurology

Parkinson's Disease

16

Pipeline Programs↗

111

Active Trials↗

91

Companies Involved↗

Parkinson's Disease is an emerging landscape with 16 programs across 91 companies. The most active players are Amneal Pharmaceuticals, LLC, Eisai, ACADIA Pharmaceuticals Inc.. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

65/100

Mech. Concentration

13/100

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Amneal Pharmaceuticals, LLC

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 2A

ACADIA Pharmaceuticals Inc.

1 program

Phase 2Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

1 program

Phase 2Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

10 of 15 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody320%Gene therapy17%Radiopharmaceutical17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 83% of 18 pipeline programs.

Analysis

Trial Status

660

clinical trials

Completed412 · 62%
Unknown status61 · 9%
Recruiting57 · 9%
Terminated51 · 8%
Active, not recruiting29 · 4%
Not yet recruiting21 · 3%
Other29 · 4%

Clinical Trials

Trial Activity

660 trials

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT06809400·127 enrolled
Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach
Recruiting·RRadboud University Medical Center·Phase 3·NCT07316296·60 enrolled
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
Recruiting·KKariya Pharmaceuticals·Phase 1·NCT06189170·88 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
Recruiting·GGain Therapeutics, Inc.·Phase 1·NCT06732180·20 enrolled
Effects of Propofol on Brain Function in Patients With Parkinson's Disease
Recruiting·—·N/A·NCT05895019·600 enrolled
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
Recruiting·SSerina Therapeutics·Phase 1·NCT07422675·40 enrolled
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
Recruiting·GGateway Institute for Brain Research·Phase 2·NCT05266417·56 enrolled
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
Recruiting·JJeffrey S. Schweitzer, MD, PhD·Phase 1·NCT06687837·8 enrolled
The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease
Recruiting·KKaohsiung Medical University Chung-Ho Memorial Hospital·N/A·NCT06548256·400 enrolled
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
Recruiting·IIl-Yang Pharm. Co., Ltd.·Phase 2·NCT04691661·40 enrolled
The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes
Recruiting·GGuangzhou Novaken Pharm Co., Ltd.·Phase 2·NCT07156773·84 enrolled
Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
Recruiting·IInnopeutics Corporation·Phase 1·NCT07371338·6 enrolled
Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Recruiting·TTanta University·Phase 2·NCT07001150·50 enrolled
DBS and Levodopa for Treating Freezing of Gait in Parkinson's Disease
Recruiting·IIRCCS Istituto delle Scienze Neurologiche di Bologna·Phase 4·NCT06316232·20 enrolled
Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease
Recruiting·—·Phase 4·NCT06710574·120 enrolled
Page 1 of 44

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)